Education
About Us
Working with TipRanks
Follow Us
Neuphoria Therapeutics (NEUP)
NASDAQ:NEUP
NEUP Stock Chart & Stats
$4.19
-$0.37(-10.36%)
At close: 4:00 PM EST
$4.19
-$0.37(-10.36%)
Day’s Range― - ―
52-Week Range$2.77 - $21.40
Previous CloseN/A
Volume31.57K
Average Volume (3M)89.21K
Market Cap
$9.95M
Enterprise ValueN/A
Total Cash (Recent Filing)$13.65M
Total Debt (Recent Filing)$85.21K
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Feb 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding2,357,613
10 Day Avg. Volume91,705
30 Day Avg. Volume89,214
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)<0.01
Price to Sales (P/S)0.48
P/FCF Ratio0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.15Price Target Upside166.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Funding And Financial PositionWith a cash balance of $14.2M and access to $22M on its ATM facility, there should be sufficient funding into 2027.
Market Opportunity And Buy RecommendationThe market cap is now under cash value, presenting an opportunity as the analyst maintains a Buy recommendation based on the PTSD opportunity.
Strategic ReviewThe company is conducting a strategic review to explore additional opportunities for BNC210 to maximize shareholder value.
Bears Say
Missed Primary EndpointThe P3 AFFIRM-1 study of BNC210 in social anxiety disorder (SAD) missed its primary endpoint, leading to a significant drop in NEUP shares.
Neuphoria Therapeutics News
NEUP FAQ
What was Neuphoria Therapeutics’s price range in the past 12 months?
Neuphoria Therapeutics lowest stock price was $2.77 and its highest was $21.40 in the past 12 months.
What is Neuphoria Therapeutics’s market cap?
Neuphoria Therapeutics’s market cap is $9.95M.
When is Neuphoria Therapeutics’s upcoming earnings report date?
Neuphoria Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is 287 days ago.
How were Neuphoria Therapeutics’s earnings last quarter?
Currently, no data Available
Is Neuphoria Therapeutics overvalued?
According to Wall Street analysts Neuphoria Therapeutics’s price is currently Undervalued.
Does Neuphoria Therapeutics pay dividends?
Neuphoria Therapeutics does not currently pay dividends.
What is Neuphoria Therapeutics’s EPS estimate?
Neuphoria Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neuphoria Therapeutics have?
Neuphoria Therapeutics has 2,357,613 shares outstanding.
What happened to Neuphoria Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Neuphoria Therapeutics?
Currently, no hedge funds are holding shares in NEUP
Company Description
Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
NEUP Stock 12 Month Forecast
Average Price Target
$11.15
▲(166.11% Upside)
Technical Analysis
TherapeuticsMD
―
Sintx Technologies
―
Rein Therapeutics
―
BioVie
―
BullFrog AI Holdings, Inc.
―
Ownership Overview
37.13% Insiders
5.29% Other Institutional Investors
52.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---